Unbalanced risk-benefit analysis of ADHD drugs – Authors’ reply
Abstract
Standardised mean differences can be difficult to translate into clinical practice.
As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between the mean value in two groups and then estimates the average amount that the experimental intervention changes in the outcome compared with that of the control intervention.
Citations
Cipriani, Andrea; Adamo, Nicoletta; Del Giovani, Cinzia; Goghill, David; Banaschewski, Tobias; Hollis, Chris; Zuddas, Alessandro; Simonoff, Emily; Cortese, Samuele. Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply. Lancet Psychiatry Correspondence 2018 5(11)P871-873
Sponsorship: Supported by the NIHR
Page last reviewed: 12 June, 2025
Metadata
Author(s): Cipriani, Andrea
Collection: 123456789/33
Subject(s): Attention Deficit Hyperactivity Disorder (ADHD), Risk Assessment
Format(s): Article
Date issued: 2018
ID: 93